R. Stevens

发表

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

P. Emery, J. Edwards, L. Szczepański, 2004, The New England journal of medicine.

JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers

Mahmoud S. Assaf, B. Bennett, R. Chopra, 2016, Clinical and Translational Medicine.

Reviews: Recommendations from an OMERACT 12 Workshop Optimal Strategies for Reporting Pain in Clinical Trials and Systematic

M. Suarez‐Almazor, P. Tugwell, M. Dougados, 2015 .

SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function

C. Edwards, A. Wells, R. Stevens, 2014 .

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

G. Schett, K. Papp, R. Stevens, 2012, Arthritis and rheumatism.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

C. Edwards, F. Blanco, C. Birbara, 2016, Annals of the rheumatic diseases.

Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0

P. Brooks, J. Fries, D. Furst, 2007, The Journal of Rheumatology.

Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.

P. Merkel, G. Hatemi, R. Stevens, 2015, The New England journal of medicine.

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

V. Strand, K. Papp, D. Fiorentino, 2013, Health and Quality of Life Outcomes.

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

M. Cutolo, E. Feist, H. Marzo-Ortega, 2016, The Journal of Rheumatology.

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

G. Girolomoni, M. Gooderham, U. Mrowietz, 2015, The British journal of dermatology.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

S. Chimenti, K. Papp, K. Reich, 2015, Journal of the American Academy of Dermatology.

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

G. Schett, R. Stevens, P. Schafer, 2010, Therapeutic advances in musculoskeletal disease.

Apremilast : a novel PDE 4 inhibitor in the treatment of autoimmune and inflammatory diseases

G. Schett, R. Stevens, P. Schafer, 2010 .

Randomized, Double‐Blind, Placebo‐Controlled Trial of Intraarticular Trans‐Capsaicin for Pain Associated With Osteoarthritis of the Knee

R. Burges, R. Stevens, J. Ervin, 2019, Arthritis & rheumatology.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

D. Gladman, E. Lespessailles, J. Gómez-Reino, 2014, Annals of the rheumatic diseases.

Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study

V. Strand, G. Schett, R. Stevens, 2013, Journal of Rheumatology.

LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

P. Mease, A. Kavanaugh, R. Stevens, 2013 .

OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

F. Blanco, R. Stevens, J. Crowley, 2013 .

OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials

G. Schett, R. Stevens, J. Gómez-Reino, 2014 .

212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement

C. Edwards, F. Blanco, C. Birbara, 2014 .

Dapsone in rheumatoid arthritis.

L. Sigal, R. Stevens, D. J. Chang, 1996, Seminars in arthritis and rheumatism.

FRI0331 Apremilast for the treatment of behçet’s syndrome: a phase ii randomized, placebo-controlled, double-blind study

P. Merkel, G. Hatemi, R. Stevens, 2013 .

Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop

G. Guyatt, M. Suarez‐Almazor, P. Tugwell, 2015, The Journal of Rheumatology.

Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014

P. Merkel, G. Hatemi, G. Mumcu, 2015, The Journal of Rheumatology.

Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from a 2014 OMERACT Workshop

G. Guyatt, M. Suarez‐Almazor, P. Tugwell, 2014 .

Treatment of arthritis with topical capsaicin: a double-blind trial.

T. Schnitzer, R. Stevens, C. Deal, 1991, Clinical therapeutics.

SAT0389 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from the Palace 4 Phase 3, Randomized, Controlled Trial

A. Wells, R. Stevens, A. Kivitz, 2014 .

Injectable Capsaicin for the Management of Pain Due to Osteoarthritis

R. Stevens, B. Lascelles, M. Chung, 2021, Molecules.

Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study

V. Strand, G. Schett, R. Stevens, 2013, The Journal of Rheumatology.

Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.

H. Paulus, M. Weisman, D. Furst, 2003, Journal of Rheumatology.

OP0167 Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study

R. Burges, J. Campbell, R. Stevens, 2017 .

Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

H. L. Wright, R. Moots, T. Spector, 2013 .

Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop

G. Guyatt, M. Suarez‐Almazor, P. Tugwell, 2015, The Journal of Rheumatology.

Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014

G. Hatemi, G. Mumcu, H. Direskeneli, 2015, The Journal of Rheumatology.

Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.

G. Hatemi, R. Stevens, H. Yazici, 2015, The New England journal of medicine.

International Conference on NeuroEndocrine Immunology in Rheumatic Diseases Steroids in NeuroEndrocrine Immunology and Therapy of Rheumatic Diseases

J. Aldag, J. Gómez-Reino, P. Mease, 2013 .